Format

Send to

Choose Destination
Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):56-64. doi: 10.1016/j.beha.2016.09.005. Epub 2016 Nov 5.

Splenic marginal zone lymphoma.

Author information

1
Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: mapiris@humv.es.
2
Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
3
Servicio de Anatomía Patológica, Hospital Virgen de la Salud, Toledo, Spain.

Abstract

Splenic marginal zone lymphoma (SMZL) is an indolent small B-cell lymphoma involving the spleen and bone marrow characterized by a micronodular tumoral infiltration that replaces the preexisting lymphoid follicles and shows marginal zone differentiation as a distinctive finding. SMZL cases are characterized by prominent splenomegaly and bone marrow and peripheral blood infiltration. Cells in peripheral blood show a villous cytology. Bone marrow and peripheral blood characteristic features usually allow a diagnosis of SMZL to be performed. Mutational spectrum of SMZL identifies specific findings, such as 7q loss and NOTCH2 and KLF2 mutations, both genes related with marginal zone differentiation. There is a striking clinical variability in SMZL cases, dependent of the tumoral load and performance status. Specific molecular markers such as 7q loss, p53 loss/mutation, NOTCH2 and KLF2 mutations have been found to be associated with the clinical variability. Distinction from Monoclonal B-cell lymphocytosis with marginal zone phenotype is still an open issue that requires identification of precise and specific thresholds with clinical meaning.

KEYWORDS:

Marginal zone; Monoclonal B-cell lymphocytosis; NOTCH2/KLF2; Splenic lymphoma

PMID:
28288718
DOI:
10.1016/j.beha.2016.09.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center